Market Research Industry Reports

Pulmonary Embolism - Pipeline Review, H2 2018

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS

Pulmonary Embolism - Pipeline Review, H2 2018

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Embolism - Pipeline Review, H2 2018, provides an overview of the Pulmonary Embolism (Cardiovascular) pipeline landscape.

Pulmonary embolism is the sudden blockage of a major blood vessel (artery) in the lung, usually by a blood clot. Symptoms include shortness of breath, chest pain, cough, leg pain or swelling, excessive sweating, rapid or irregular heartbeat and dizziness. Predisposing factors include High blood pressure and cardiovascular disease. Treatment includes anticoagulants and thrombolytics.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Pulmonary Embolism - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Pulmonary Embolism (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pulmonary Embolism (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Embolism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II and Preclinical stages are 2, 2 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Pulmonary Embolism (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Embolism (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Pulmonary Embolism (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pulmonary Embolism (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pulmonary Embolism (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Embolism (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pulmonary Embolism (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pulmonary Embolism (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Pulmonary Embolism - Overview
Pulmonary Embolism - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Pulmonary Embolism - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pulmonary Embolism - Companies Involved in Therapeutics Development
Accu-Break Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Dong-A Socio Holdings Co Ltd
F. Hoffmann-La Roche Ltd
Tasly Pharmaceutical Group Co Ltd
Verseon Corp
Pulmonary Embolism - Drug Profiles
DS-1040 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Heparin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Cyclooxygenase and Glycoprotein IIb/IIIa for Pulmonary Embolism and Hematological Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRX-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
urokinase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VE-1902 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VE-2851 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
warfarin potassium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pulmonary Embolism - Dormant Projects
Pulmonary Embolism - Discontinued Products
Pulmonary Embolism - Product Development Milestones
Featured News & Press Releases
Nov 28, 2016: Research to Be Presented at ASH Annual Meeting Shows Verseon’s New Class of Anticoagulants Prevents Thrombosis While Preserving Platelet Function
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer


List Of Tables


Number of Products under Development for Pulmonary Embolism, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pulmonary Embolism - Pipeline by Accu-Break Pharmaceuticals Inc, H2 2018
Pulmonary Embolism - Pipeline by Daiichi Sankyo Co Ltd, H2 2018
Pulmonary Embolism - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2018
Pulmonary Embolism - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
Pulmonary Embolism - Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2018
Pulmonary Embolism - Pipeline by Verseon Corp, H2 2018
Pulmonary Embolism - Dormant Projects, H2 2018
Pulmonary Embolism - Discontinued Products, H2 2018


List Of Figures


Number of Products under Development for Pulmonary Embolism, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018


Pulmonary Arterial Hypertension - Pipeline Review, H2 2018

Pulmonary Arterial Hypertension - Pipeline Review, H2 2018The latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Arterial Hypertension - Pipeline Review, H2 2018, provides an overview of the Pulmonary Arterial

USD 2000View Report

Pulmonary Embolism - Pipeline Review, H2 2018

Symptoms include shortness of breath, chest pain, cough, leg pain or swelling, excessive sweating, rapid or irregular heartbeat and dizziness.

USD 2000View Report

Thromboembolism - Pipeline Review, H2 2018

Thromboembolism - Pipeline Review, H2 2018Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Thromboembolism - Pipeline Review, H2 2018, provides an overview of the Thromboembolism (Cardiovascular) pipeline landscape.When

USD 2000View Report

Global Pulmonary Embolism Market Research Report 2018

Pulmonary Embolism Report by Material, Application, and Geography Global Forecast to 2022 is a professional and in-depth research report on the worlds major regional market conditions, focusing on the

USD 2850View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 2000
  • Site Licence    USD 4000
  • Enterprise Wide Licence    USD 6000
$ 2000

Reports Details

Published Date : Aug 2018
No. of Pages :37
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :Global Markets Direct
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube